Colorectal cancer cells enter a diapause-like DTP state to survive chemotherapy SK Rehman, J Haynes, E Collignon, KR Brown, Y Wang, AML Nixon, ... Cell 184 (1), 226-242. e21, 2021 | 293 | 2021 |
Regulation of CD133 by HDAC6 promotes β-catenin signaling to suppress cancer cell differentiation AB Mak, AML Nixon, S Kittanakom, JM Stewart, GI Chen, J Curak, ... Cell reports 2 (4), 951-963, 2012 | 200 | 2012 |
Small molecule antagonists of the Wnt/beta-catenin signaling pathway target breast tumor-initiating cells in a Her2/Neu mouse model of breast cancer RM Hallett, MK Kondratyev, AO Giacomelli, AML Nixon, A Girgis-Gabardo, ... PloS one 7 (3), e33976, 2012 | 120 | 2012 |
Post-translational regulation of CD133 by ATase1/ATase2-mediated lysine acetylation AB Mak, M Pehar, AML Nixon, RA Williams, AC Uetrecht, L Puglielli, ... Journal of molecular biology 426 (11), 2175-2182, 2014 | 59 | 2014 |
Ontogeny and Vulnerabilities of Drug-Tolerant Persisters in HER2+ Breast Cancer CA Chang, J Jen, S Jiang, A Sayad, AS Mer, KR Brown, AML Nixon, ... Cancer discovery 12 (4), 1022-1045, 2022 | 58 | 2022 |
The Mixed Lineage Leukemia (MLL) Fusion–Associated Gene AF4 Promotes CD133 Transcription AB Mak, AML Nixon, J Moffat Cancer research 72 (8), 1929-1934, 2012 | 54 | 2012 |
A rapid in vitro methodology for simultaneous target discovery and antibody generation against functional cell subpopulations AML Nixon, A Duque, N Yelle, M McLaughlin, S Davoudi, NM Pedley, ... Scientific reports 9 (1), 842, 2019 | 11 | 2019 |
Characterization of the minimal residual disease state reveals distinct evolutionary trajectories of human glioblastoma MA Qazi, SK Salim, KR Brown, N Mikolajewicz, N Savage, H Han, ... Cell Reports 40 (13), 2022 | 4 | 2022 |
System and method for profiling antibodies with high-content screening (hcs) S Cooper, O Kraus, M London, G Watson, A Nixon, E Koch, È Dumoulin, ... US Patent App. 17/918,882, 2023 | | 2023 |
AI/ML-driven discovery of a novel proteoglycan for precision targeting of ADCs for disruption of stromal barriers and direct anti-tumor activity E Koch, M London, A Berkley, A Nixon, S Phippen, K White, A Hanson, ... Cancer Research 82 (12_Supplement), 388-388, 2022 | | 2022 |
TMOD-23. DYNAMIC PATTERNS OF GLIOBLASTOMA CLONAL EVOLUTION IN RESPONSE TO CHEMORADIOTHERAPY M Qazi, C Venugopal, P Vora, A Nixon, K Desmond, M Singh, S Neil, ... Neuro-Oncology 20 (Suppl 6), vi273, 2018 | | 2018 |
The Development of an Antibody Panel Against Immunoglobulin Superfamily Member 8: A Novel Regulator of Extracellular Matrix Interaction K Sood, A Nixon, J Moffat, S Sidhu PROTEIN SCIENCE 27, 236-237, 2018 | | 2018 |
Integrins are key mediators of cell state and tumour heterogeneity AML Nixon University of Toronto (Canada), 2018 | | 2018 |
TMOD-06. CLONAL DYNAMICS OF HUMAN GLIOBLASTOMA IN RESPONSE TO CHEMORADIOTHERAPY M Qazi, A Nixon, D Bakhshinyan, C Venugopal, P Vora, K Brown, ... Neuro-Oncology 19 (Suppl 6), vi255, 2017 | | 2017 |
Developing models of therapy resistance for the identification of treatment-refractory cell population (s) in human glioblastoma M Qazi, P Vora, C Venugopal, D Bakhshinyan, A Nixon, K Brown, ... NEURO-ONCOLOGY 18, 207-207, 2016 | | 2016 |
Modelling Therapy Resistance for the Identification of Treatment-Refractory Cell Population (s) in Human Glioblastoma MA Qazi, P Vora, C Venugopal, D Bakhshinyan, A Nixon, N McFarlane, ... Canadian Journal of Neurological Sciences 43 (S4), S1-S1, 2016 | | 2016 |
High-complexity neutral genomic barcoding technology reveals extensive clonal dynamics in multiple human cancer model systems AML Nixon, KR Brown, J Haynes, LK Donovan, MD Taylor, CW O’Brien, ... Cancer Research 76 (14_Supplement), 2384-2384, 2016 | | 2016 |
ORAL PRESENTATIONS 10 JUNE 2016 MA Qazi, P Vora, C Venugopal, D Bakhshinyan, A Nixon, N McFarlane, ... Young, 2016 | | 2016 |
Investigating the function and regulation of CD133 using functional genomics and computational methods AML Nixon, A Sayad, T Hart, J Tomic, J Moffat CLINICAL & EXPERIMENTAL METASTASIS 32 (3), 226-226, 2015 | | 2015 |
Running title (60 characters): Characterization of lapatinib drug-tolerant persisters. A Che-wei, S Jiang, A Sayad, KR Brown, A Nixon, A Dhabaria, KH Tang, ... | | |